FarmaKology Newsletter - Issue #73

May 17, 2021

Today's Startup

REVOLUTION Medicines

REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms, and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

News

PrecisionLife and Cyclica sign strategic partnership combining leading data-driven biology and chemistry platforms to create a rapid innovation engine for drug discovery

PrecisionLife Ltd. (“PrecisionLife”), the leading combinatorial analytics company driving understanding of disease biology and patient stratification, and Cyclica Inc. (“Cyclica”), the partner of choice for data-driven drug discovery, announced that they have entered into a strategic partnership to co-market and offer their complementary computational platforms as an integrated drug discovery factory. The companies will initially collaborate on up to 30 pharma and biotechnology drug discovery programs over the next two years.

LianBio Partners With Landos to Commercialize Colitis, Crohn’s Drugs in China

Landos Biopharma based in Blacksburg, Va., partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets. Omilancor is an oral, gut-restrict LANCL2 agonist being developed for ulcerative colitis (UC), Crohn’s disease (CD), and Eosinophilic Esophagitis (EoE). NX-13 is an oral, gut-restricted compound targeting NLRX1 being developed for UC and CD.

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers. A global pivotal Phase 3 study is expected to start in the coming weeks.

Lilly signs pact with Natco to accelerate the availability of baricitinib for Covid-19 patients

Eli Lilly and Company said on Monday it has issued an additional royalty-free, non-exclusive voluntary license to Natco Pharma, a local pharmaceutical manufacturer of generic medicines. Natco will collaborate with Lilly to accelerate the availability of baricitinib in India and improve local treatment options for patients battling Covid-19 patients.

Podcast

Listen to Episode 82: Integrating Sustainability Into Biopharma Strategy and eighty-two more episodes by Pharm Exec Podcast, free! No signup or install needed. Episode 82: Integrating Sustainability Into Biopharma Strategy. Behind the Creative...Inspiring Award-Winning Creative.

Video

FarmaKology’s Substack

Discussion about this post